Annie Hubert, PhD Alliance for Regenerative Medicine

Annie Hubert is the Director of European Public Policy at the Alliance for Regenerative Medicine (ARM).  ARM is the preeminent global advocacy, multi-stakeholder organisation to foster research, development, investment and commercialization of advanced therapies and regenerative medicine worldwide.

Annie represents and manages the activities of ARM in Europe and brings over 30 years’ experience in European regulatory affairs, pricing and reimbursement, market access and government affairs. The activities of ARM have steadily grown during the last few years and the EU Committees in regulatory affairs and reimbursement/market access, created in 2014, now group together over 50 company representatives originating from Europe, US or elsewhere.

Since 2012, Annie is also Managing Director of ESAH (Expert Services and Advice in Healthcare sprl/bvba), a consulting company providing services in healthcare biotech, with expertise in market access, regulatory and economic policy and government affairs relating to biopharmaceuticals and advanced therapies. Starting in June 2012, she has founded and directs Co-ACT, an association grouping together small and medium-size enterprises (SMEs) developing advanced therapies in Belgium.

Previously, Annie worked in various positions in regulatory affairs, market access and government affairs for several biopharmaceutical companies, including Amgen (between 2001 and 2011), Warner-Lambert (now Pfizer), Pharmacia (now Pfizer) and Beecham Research Laboratories (now GSK).

She has been an active member in various industry associations and has led a number of industry initiatives in the areas of Biotechnology and Health Technology Assessment. She lectured on biotechnology topics in different educational courses for healthcare professionals and students in Belgium.

Annie holds a Master in Pharmacy (UCL, Belgium) and is qualified as industrial pharmacist since 1983. She is a Belgian national and is established nearby Brussels.